Surmodics has announced the commercial release of the Pounce XL thrombectomy system, the latest in a suite of Pounce thrombectomy systems that provide endovascular removal of acute or chronic clot from peripheral arteries.
Intended for removal of thrombi and emboli from peripheral arteries ranging from 5.5–10mm in diameter, sizes typical of iliac and femoral arteries, the Pounce XL thrombectomy system accompanies the Pounce and Pounce low-profile thrombectomy systems, which are intended for use in 3.5–6mm and 2–4mm peripheral arteries, respectively. With a combined vessel diameter range of 2–10mm, the Pounce thrombectomy platform provides a standalone solution for rapid removal of peripheral arterial thrombi and emboli throughout the lower and upper extremities.
The Pounce XL thrombectomy system has been in limited market release (LMR) since January 2025. Anna Marjan, a vascular surgeon at Allina Health Mercy Hospital in Coon Rapids, USA, was among the physicians who used the Pounce XL thrombectomy system during the product’s LMR, a press release made by the company describes.
“Removing organised clot from large peripheral arteries without a surgical cutdown can be very challenging,” she said. “In our first use of the Pounce XL thrombectomy system we were able to extract a large amount of acute and subacute clot from the infrarenal aorta and common iliac arteries in a severely ischemic patient with just three passes of the device. Avoiding surgical cutdown reduces the need for general anaesthesia and reduces risk of surgical-site infection, which benefits patients. The Pounce thrombectomy platform is my first-line, go-to solution for endovascular thrombectomy in peripheral arteries.”
Surmodics states that the effectiveness and safety of the Pounce and Pounce LP thrombectomy systems are supported by real-world data from the PROWL registry, an open-label, retrospective, multicentre, US study of the Pounce thrombectomy platform for the removal of emboli and thrombi in the peripheral arterial vasculature. In an interim analysis of 74 patients with acute, subacute, and chronic native infrainguinal vessel limb ischaemia, average Pounce thrombectomy platform use time was 20.3 minutes, with 79.7% of patients receiving no additional clot removal treatment of the target lesion after Pounce thrombectomy platform use. Device-related adverse events were limited to one report of flow-limiting dissection.
“The addition of the Pounce XL thrombectomy system fulfils our vision of providing a simple, effective platform for removing peripheral arterial blood clots throughout the leg,” said Gary Maharaj, president and chief executive officer of Surmodics. “When minutes matter, physicians appreciate the availability of a readily deployable solution with a track record of dependable and safe results. We’re proud of the growing clinical adoption of this product and the benefits it is bringing to limb ischaemia patients in need of urgent care.”
